Dr. Kelly and her colleagues synthesized a panel of PDCs aiming at the precise treatment of pulmonary fibrosis, where nintedanib - a potent kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis - and a peptidomimetic targeting αVβ6 integrin - which is a receptor overexpressed in fibrotic tissues - are connected by different linkers.…